Aquestive Therapeutics (NASDAQ:AQST) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares.Aquestive Therapeutics is selling 16,666,667 shares of AQST stock for $4.50 each in this public offering. There’s also a 30-day option for underwriters to acquire an additional 2.5 million shares at that same price.Aquestive Therapeutics is expecting $75 million in gross proceeds from the stock offering. The company will use these funds to continue the deve ...

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting disc ...

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of ...

Aquestive Therapeutics, Inc. (AQST) shares jumped 16% on Mar 15 after the company achieved the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to treat severe allergic reactions. The stock price surge was also likely boosted by findings from the FDA Type C meeting.AQST’s Anaphylm is a non-invasive oral epinephrine product candidate. It has the potential to offer greater convenience of use compared with autoinjectors, ...

Aquestive Therapeutics (AQST) shares ended the last trading session 16% higher at $6.09. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 93% gain over the past four weeks.The sudden surge in the stock price can be attributed to Aquestive's announcement regarding achieving the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to ...

Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectorsAnaphylm exposure levels (AUC) are comparable to autoinjectors for 30 minutes after dosing Anaphylm is well-tolerated with no serious adverse events Company receives positive Type C meeting feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical development of Anaphylm Company reaffirms goal of filing NDA before the end o ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Carl Kraus - Chief Medical Officer Conference Call Participants François Brisebois - Oppenheimer Jason Butler - Citizens JMP Securities Andreas Argyrides - Wedbush Thomas Flaten - Lake Street Capital Markets Ram Selvaraju - H.C. Wainwright James Molloy - Alliance G ...

Q4 2024 Earnings Supplemental Materials March 5, 2024 Advancing medicines. Solving problems. Improving lives. 1 ...

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.11 per share when it actually produced a loss of $0.03, delivering a surprise of 72.73%.Over the last four quar ...

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024Reaffirms anticipated FDA decision on Libervant™ (diazepam) Buccal Film application in April 2024Provides full year 2024 financial guidanceHosts investment community conference call on March 6, 2024 WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pha ...